Cargando…

Treatment patterns and characteristics of European patients with castration-resistant prostate cancer

BACKGROUND: European treatment guidelines recommend the use of hormonal therapy for the treatment of advanced prostate cancer, including castration-resistant prostate cancer (CRPC), but there is little understanding of how common practices in prostate cancer treatment compare across Europe. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sternberg, Cora N, Baskin-Bey, Edwina S, Watson, Mark, Worsfold, Andrew, Rider, Alex, Tombal, Bertrand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226263/ https://www.ncbi.nlm.nih.gov/pubmed/24206580 http://dx.doi.org/10.1186/1471-2490-13-58

Ejemplares similares

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease
por: Suzuki, Hiroyoshi, et al.
Publicado: (2021)

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
por: Recine, Federica, et al.
Publicado: (2015)

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
por: Shore, Neal, et al.
Publicado: (2020)

Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)
por: George, Daniel J., et al.
Publicado: (2022)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
por: Higano, Celestia S., et al.
Publicado: (2023)

Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER
por: Joshua, Anthony M., et al.
Publicado: (2022)

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study
por: Attard, Gerhardt, et al.
Publicado: (2019)

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
por: Tombal, B., et al.
Publicado: (2022)

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
por: Bryce, A H, et al.
Publicado: (2017)

Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry
por: Verry, Camille, et al.
Publicado: (2022)

Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer
por: Saad, Fred, et al.
Publicado: (2023)

Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer
por: O’Sullivan, Joe M., et al.
Publicado: (2022)

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial
por: Devlin, Nancy, et al.
Publicado: (2017)

Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials
por: Saad, F, et al.
Publicado: (2017)

Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practice
por: Bögemann, Martin, et al.
Publicado: (2023)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
por: Arnold, Peter, et al.
Publicado: (2021)

Chemoprevention of prostate cancer with nutrients and supplements
por: Van Poppel, Hendrik, et al.
Publicado: (2011)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Lymphangitic Pulmonary Metastases in Castrate-Resistant Prostate Adenocarcinoma
por: Meyer, Andrew, et al.
Publicado: (2012)

Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer
por: Peter, Madonna R., et al.
Publicado: (2021)

The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials
por: Tombal, Bertrand, et al.
Publicado: (2021)

Transdermal estradiol in castrate and chemotherapy resistant prostate cancer
por: Stein, Mark, et al.
Publicado: (2012)

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
por: Kim, Yejin, et al.
Publicado: (2016)

Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over?
por: Tombal, Bertrand, et al.
Publicado: (2012)

A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE
por: Payne, Heather, et al.
Publicado: (2021)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
por: de Leeuw, Renée, et al.
Publicado: (2020)

ERG induces taxane resistance in castration-resistant prostate cancer
por: Galletti, Giuseppe, et al.
Publicado: (2014)

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
por: Bahl, A., et al.
Publicado: (2013)

Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer
por: Anton, Angelyn, et al.
Publicado: (2021)

Cardiovascular risk during hormonal treatment in patients with prostate cancer
por: Van Poppel, Hein, et al.
Publicado: (2011)

Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer
por: Gunawan, Florence, et al.
Publicado: (2019)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Chemotherapy options in castration-resistant prostate cancer
por: Teply, Benjamin A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_km7p4mrkn4mleqa3o3dsk5gv15